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P-sitosterol/polyethylene glycol complexes were prepared by solution blending in
1,2-dichloroethane. 1,2-Dichloroethane is a good solvent for the two components. The
complexes were studied by Nuclear Magnetic Resonance (NMR) spectroscopy and
Differential Scanning Calorimetry (DSC). These complexes have the possibility of
reducing the swelling of benign prostatic hyperplasia and diminishing inflammation. P-
sitosterol is hydrophobic and thus it is difficult to deliver the sterol into aqueous systems.
Aqueous system delivery is required for effective blood circulation. Polyethylene glycol
was used because of its amphiphilic properties. Proton NMR ('HNMR) of the complexes
shows that the methylene (CH2) protons of the PEG are slightly shifted because of its
non-covalent interaction with P-sitosterol. The complex formation was supported by 2-D
NMR (NOESY) spectroscopy. NOESY spectra show cross peaks, indicating interaction
between the two components. DSC of the complexes show thermal characteristics that
are different from the individual components. In particular, the PEG in the complexes
shows a lower melting point and decreased crystallinity compared to the pure PEG. The
melting point is lowered from 62 °C to 55 °C for the PEG 35,000/p-sitosterol (10%)
complex. The NMR and DSC studies suggest the formation of a relatively stable(3-
sitosterol/polyethylene glycol complex.
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Prostate cancer is the second most diagnosed cancer in the world.1 However, the
number of prostate cancer survivors has been increasing in the past 10 years by an
estimated 200,000 men every year.2 The prostate cancer survivor population in the United
States approached 2.8 million survivors in January 2012.2 Most ofthem (62%) are aged
70 and older with multiple comorbid conditions.3 This increase in prostate cancer
survival rates is due to the availability of different treatment options including
radiotherapy, chemotherapy, surgery, hormone therapy, immunotherapy, and in many
cases, a combination is needed to produce the intended curative results.
A patient's prognosis depends on early detection, complete surgical removal and
effective radiotherapy, chemotherapy, or other treatments. Unfortunately, each of the
treatments has advantages and disadvantages. For example, chemotherapy induces many
adverse effects such as anemia, hair loss, fatigue, appetite change, nausea, vomiting,
diarrhea, and constipation. An effective approach to decrease or minimize side effects is
via multiple or combined treatment options.
The most important factor in prostate cancer survival is early and precise
detection by regular screening examinations. It is difficult to determine who is at risk of
developing any type of cancer. However, eliminating tobacco and alcohol usage, sun
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exposure and obesity; having a healthy diet, and engaging in physical activity can
decrease the incidence of cancer.4
Once cancer is detected, it is important to reduce the swelling related to the
existing inflammation before starting any type of treatment. Phytosterols are medications
that diminish inflammation.
1.2 Phytosterols
Phytosterols, as the name indicates, are a group of steroids that are produced by
plants. They have a cholesterol-like molecular structure and are present in all plant based
foods, especially in vegetable oils. Phytosterols are structurally similar to the cholesterol
produced by animal cells. Due to their structural similarity to cholesterol, the function of
phytosterols in plant cells is similar to that of cholesterol in animal cells.5 Phytosterols
are triterpenes that act as structural components and stabilize phospholipid bilayers in
plant cell membranes.6
Phytosterols were initially studied as a cholesterol-lowering agent because they
reduce the absorption of dietary cholesterol and thus offer protection from cardiovascular
diseases. Later, they were found to have many other beneficial uses for human health.
Most phytosterols have 28 or 29 carbon atoms with one or two carbon-carbon double
bonds, one is in the sterol nucleus and another one may be present in the alkyl side






Figure 1. Chemical structure of phytosterols and their similarity to cholesterol.8'9'10
1.3 p-sitosterol
One of the most abundant dietary phytosterols is P-sitosterol (24-
ethylcholesterol), which is found in many nuts, seeds, and beans.11'12 It has been used in
many natural remedies such as stinging nettle, devil's claw, and saw palmetto.13'14'15 As it
is one of the phytosterols it has a structure similar to cholesterol. Therefore, it has been
studied as a blood cholesterol-lowering agent, which may be due to its ability to prevent
the intestinal absorption of cholesterol.16'17 P-sitosterol has also shown anti-inflammatory
and analgesic properties in various animal models. It was determined that it has an anti-
inflammatory activity, similar to hydrocortisone and oxyphenbutazone, and an antipyretic
effect similar to acetyl salicylic acid.18 In another study, it was found to have an
anthelmintic property.
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More importantly, P-sitosterol has been found to reduce the symptoms of benign
prostatic hyperplasia.20'21 Moreover, it decreases the incidence of colon, prostate and
breast cancers among Asian men and women who consume significant amounts of |3-
sitosterol.8'9'10 p-sitosterol has been found to inhibit growth and also shown to have
cytotoxic effects against a range of cancer cell lines. '
1.4 Polyethylene Glycol
Unfortunately, the free form of P-sitosterol is not soluble in water.24 It has a
molecular weight of 414.7067 Da and a log P value of 9.3, which indicates high
hydrophobicity.25 Due to its insolubility in water, P-sitosterol has limited applications.
Many studies have been carried out to increase its solubility either in oil or in water. One
study has reported that the chemically modification of the 3-hydroxy group with fatty
acids increases its solubility in fats.26 The ester compounds resulting from the
esterification of P-sitosterol were studied and found to have the same cholesterol-
lowering effects as the parent molecule.
Because of the beneficial effect of P-sitosterol in the treatment of prostate cancer
and due to its limited hydrophilicity, P-sitosterol has been covalently conjugated with
PEG (Fig. 2). The conjugated structure has shown increased solubility in aqueous
medium. The conjugation required a two-step chemical synthesis and is shown in Figure
3. The first step was to synthesize an intermediate (carboxyethyl-P-sitosterol, CES),
which imparts a carboxylic functionality to P-sitosterol, and the second step was the














Figure 3. Synthesis of P-sitosterol and PEG conjugate
24
An easier approach to increase water solubility would perhaps be to prepare a (3-
sitosterol and PEG complex by solution blending of the two components. The resulting
complex would have a hydrophobic moiety of P-sitosterol and a hydrophilic part of PEG.
This approach was utilized to improve water solubility of a co-poly(ester amide) by
complexation of the hydrophobic poly(ester amide) with PEG.27
Several other approaches have been proposed to increase the water solubility of P-
sitosterol and they were mainly by preparing formulations with emulsifiers. Lecithin
emulsified micelles of P-sitosterol were found to have a cholesterol-lowering effect
similar to pure P-sitosterol.28 An other attempt to increase p-sitosterol's water solubility
was the formulation of P-sitosterol containing liposomes and this increased its chemo-
preventive effect.29 In addition an inclusion complex of P-sitosterol in P-cyclodextrin has
been studied and found to have improved the water solubility of P-sitosterol.30
A simple method for increasing the hydrophilicity of hydrophobic agents is to
form a complex with polyethylene glycol (PEG). Many of the past and current studies in
pharmaceutical research focused on the ability of PEG to modify the pharmacokinetic
properties of drugs and drug carriers. Shielding or bonding the administered drugs to
PEG changes their pharmacokinetics resulting in prolonged blood circulation times. This,
in turn, prevents the recognition of the drug as foreign and allows it to reach its site of
action before being cleared from the body. Therefore, most liposomal and micellar




2.1 Theories of Cancer Protection
The exact mechanism of cancer protection by P-sitosterol is not known. Several
theories have been developed to explain this effect and the findings in these areas are as
the follows:
• Effect of (3-sitosterol on Membrane Structure
Due to its similarity to cholesterol, an integral lipid component of biological
membranes, (3-sitosterol incorporation into membranes has been studied. P-sitosterol
incorporation resulted in a 50% decrease in sphingomyelin and an 8% increase in
phosphatidyl choline.32 This may cause an alteration in some signal transduction
pathways.
• Effect of p-sitosterol on Membrane Fluidity
Membrane fluidity is influenced by the lipid composition of membranes.33
Fluidity should be kept within a very narrow range for the proper function of membranes.
Incorporation of P-sitosterol into membranes decreased fluidity.
• Effect of P-sitosterol on Membrane-Bound Enzymes
P-sitosterol incorporation into membranes increases the activities of some fatty
acid desaturases in the liver.34 However, it decreases the activities of hepatic and prostatic
5-a-reductase and prostatic aromatase, membrane-bound enzymes involved in
the metabolism of testosterone in rats.35 These two enzymes metabolize testosterone
into androgens and estrogens, which play a role in the development of prostate
hyperplasia and prostate cancer.36'37
• Effect of P-sitosterol on Signal Transduction Pathways
As previously mentioned, incorporation of P-sitosterol into cell membrane causes
changes in membrane phospholipid, mainly in sphingomyelin, which may indicate that P-
sitosterol has an effect on the sphingomyelin cycle (Fig. 4). By investigating this pathway
in HT-29 cells and LNCaP cells, it was found that there is an activation of the cycle and
an increase in the production of ceramide.38 Ceramide has been suggested to activate
protein phosphatase 2A (PP2A) as an intermediate step for the action of ceramide on cell
growth and apoptosis. P-sitosterol supplementation caused an increase in the activity but
not the amount of PP2A in LNCaP cells.
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Figure 4. P-sitosterol activation of sphingomyelin cycle.8'9'10 SIT: P-sitosterol, SPh:
Sphingomyelin and PP2A: protein phosphatase 2A.
• Effect of P-sitosterol on Apoptosis
The rate of tumor growth depends on the balance between the rates of cell
proliferation and apoptosis. The effect of P-sitosterol on apoptosis, or programmed cell
death, has been studied in two tumor cell lines, MDA-MB-231 and LNCaP cells.8'10 In
both cell lines, it was found that P-sitosterol stimulated apoptosis by four to six folds
above control levels after 3-5 days of treatment.
• Effect of P-sitosterol on immune function
It was found that a mixture of P-sitosterol and its glucoside at a mass ratio of
100:1 potentiate human peripheral blood lymphocyte proliferation in vitro and enhanced
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T-cell proliferation upon stimulation in vitro.39 The exact mechanism by which P-
sitosterol may stimulate immune system function is not fully understood.
• Effect of P-sitosterol on Neutral and Acidic Sterols in the Colon
Primary bile acids and cholesterol are converted to secondary bile acids and
coprostanol, respectively, in the large intestine by bacterial action. A high level of these
modified sterols in the colon plays a role in the development of colon cancer. Dietary P-
sitosterol alters the level of fecal sterols by acting on colonic bacteria and causing
alteration of cholesterol absorption.40
2.2 PEGylation Concept
The concept of PEGylation was not known until the late 1970s, and by the 1990s,
it was being used in many drug carrier systems. Abuchowski et al first reported
PEGylation of proteins in 1977.41'42 They showed that PEGylated albumin was non-
immunogenic and PEGylated liver catalase had a long blood circulation time (48h) while
maintaining the activity of the enzyme.41'42
Many PEGylated DNA, RNA, proteins, polypeptides, and small molecules have
been found to be more stable and efficient compared to native drugs and have reached the
market as commercial products.31 The pharmacokinetics of PEG surface covered
poly(lactic-co-glycolic acid) microspheres was reported by Gref et al in 1994. It was
found that the liver removed 66% of then on-coated particles in only 5 minutes after
injection while it captured less than 30% of the 20 kDa PEG-coated nanospheres 2 hours
after injection.
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Since the early 1960s, liposomes have been used as versatile drug-delivery
systems.44'45 In 1990, it was reported that the PEGylation of liposome had enhanced
blood circulation times of liposomes.46 Conventional liposomes were reported to be
completely cleared from blood after 5 hours, whereas 49% of PEGylated liposomes were
still circulating in the blood after the same amount of time.4
Kabanov et al. were the first to use PEGas a hydrophilic part of linear diblock
copolymers for the formation of micelles.47 Kwon and Kataoka used PEG-containing
block copolymer micelles as drug-delivery carriers.48 Polymers used as vectors for gene
transfection in gene therapy must have special properties due to the charged nature of
DNA. However, the cationic non-viral vectors are toxic and have a short half-life in the
body. The PEGylation of these carriers decreased their depositions in the lung and
lowered initial toxicities compared to unmodified complexes.49 These beneficial effects
may be due to a lower aggregation of the complexes, a decreased interaction with blood
constituents, and a lower rate of filtration by pulmonary capillaries. Moreover, PEG
covered carriers have a slower uptake by the organs (liver and spleen) of the
reticulendothelial system (RES).50 PEGylated poly(l-lysine) (PLL) showed an increased
amount of polyplex (15% to 69%) circulating in the blood.50
PEGylation of drugs, liposomes, and nanocarriers reduces their renal filtration,
decreases enzymatic degradation, and diminishes uptake by the RES. Therefore,
PEGylated drugs have a prolonged half-life in the body and an enhanced bioavailability.
This decreases the frequency of drug administration and lowers the amount of the drug
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administered, which leads to an improvement in the life quality of the patient and
reduction in clinical costs.31'51
2.3 Polyethylene Glycol Applications
The molecular weights ofPEG used in different pharmaceutical and medical
applications ranges from 400 Da to about 50 kDa. To conjugate with low-molar-mass
drugs such as small molecules, oligonucleotides, and siRNA, PEG with a molar mass of
20 kDa to 50 kDa is often used. This avoids fast renal clearance because the size of the
conjugates is above the renal clearance threshold. For larger drugs, such as antibodies or
nano particulate systems, PEGs with lower molar weights of 1 kDato 5kDa are mostly
used. This decreases the opsonization and subsequent elimination by the RES.52
Pharmacokinetic studies of PEG on a wide range of animal species such as rats,
mice, guinea pigs, monkeys, and dogs have been carried out. These studies determined
increasing the molar mass ofPEG decreased its gastrointestinal absorption. Therefore,
PEGs with a molar mass of 4 kDa to 6 kDa are not absorbed over 5 hours in rat intestines,
and lower molar-mass PEGs of about 1 kDa have a slight absorptive effect of about 2%.
PEG is mainly excreted by the kidneys. After intravenous injection of 1 g of 1 kDa and 6
kDa PEG, 85% and 96% of PEGs were excreted in human urine in 12 hours,
respectively.53 As reported by IPCS, LD50 values for 6 kDa PEG (50%solution in water)
in mice, rats, rabbits, and guinea pigs after oral intake were higher than 50 g/kg of body
weight. After intraperitoneal (i.p.) administration, 6 kDa PEG showed LD5o value of 5.9
and 6.8 g/kg in mice and rats, respectively.54
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Due to its success in drug-delivery applications, PEG has been used in other
medical fields. PEG reduces the aggregation of red blood cells and improves the blood
compatibility of poly(vinylchloride) bags. Therefore, it is used in blood and organ
storage.55'56 Cardiovascular devices, such as stents made from PEG copolymers showed
decreased thrombosis.57 Furthermore, PEG is used in pharmaceutical preparations as an
excipient for parenteral, topical, nasal, and ocular applications, and it is used as the active
ingredient in laxatives.
PEG has been extensively used in the formation of micelles by covalent bonding
to a hydrophobic moiety to from a hydrophobic core and a hydrophilic shell. The
hydrophilic shell allows the micelles to escape uptake by the reticuloendothelial system
allowing the micelles more time in circulation as in the case of PEG/PLA and PEG/PCL
micelles.58 PEG has been also used to increase the stability of liposomes and increase
their residence time in circulation by allowing them to remain undetected by the RES
system.59 Solid lipid nanoparticles having a PEG surface coverage has been studied and
found to increase the half-life of hydrophobic drugs such as Noscapine.60 Moreover, PEG





Polyethylene glycol (MW 2,000, 8,000, and 35,000) was obtained from Sigma-
Aldrich Chemical Company. P-sitosterol(Practical Grade M.W. 414.7) was purchased
from MP Biomedicals Inc. 1,2 Dichloroethane(99%) was obtained from Sigma-Aldrich
Chemical Company. Benzene was purchased from Fisher Chemical Company.
Chloroform-D, (99.8%), for NMR was acquired from Acros Organics Company. All
materials were used as received.
3.2 Methods
3.2.1 Preparation of P-sitosteroland Polyethylene Glycol (MW 2,000,8,000, and
35,000) complexes
One gram (lg) of polyethylene glycol (MW 2,000, 8,000, 35,000) of different
molecular weights was added to three different round bottom flasks equipped with
magnetic stirrers and dissolved in 1,2-dichloroethane (10 mL). The solutions were stirred
until the polymers were completely dissolved and this process took 24 hours at room
temperature. Also, 0.1 g of (3-sitosterol powder was dissolved in 1,2-dichloroethane (10
mL) in three separate flasks by stirring for 24 hours at room temperature. Each of the
flasks containing polyethylene glycol was mixed with a flask containing (3-sitosterol and
stirred overnight. Most of the 1,2-dichloroethane was removed by nitrogen flushing for 6
14
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hours. Lastly a few drops of benzene were added to the flasks and the samples freeze
dried to obtain white powders. The powders were dried on the vacuum line for 48 hours.
3.3 Instrumentations
3.3.1 Nuclear Magnetic Resonance Spectroscopy
Proton NMR ('H-NMR) spectra in solution state were obtained using a Bruker
AVANCE 500 MHz spectrometer at room temperature with chloroform (CDC13) as the
solvent. 2D NMR experiments (NOESY) were also carried out using the AVANCE 500
NMR spectrometer.
3.3.2 Fourier Transform-Infrared Spectroscopy
The P-sitosterol/polyethylene glycol complexes were crushed in a mortar and
pestle with 98% potassium bromide (KBr) until a fine powder was obtained. The samples
were molded into pellets and IR spectra recorded.
3.3.3 Differential Scanning Calorimetry
Differential Scanning Calorimetry was carried out on a TA instruments DSC
Q2000 at a heating rate of 10°C per minute between the temperature ranges of 25°C to
200°C.The DSC was calibrated using Indium under a nitrogen gas atmosphere. All
samples were quenched cooled before acquiring the thermograms. The samples were
heated to 200°C and cooled to 25°C before obtaining the heating cycle at 10 °C. The
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glass transition temperatures were reported from the second heating cycle. The heating
rate in the first and second heating cycles remained the same.
3.3.4 Carbon TipRelaxation
Rotating frame carbon spin lattice relaxation (Tip) of solid samples was
determined at room temperature on a Bruker 500 MHz AVANCE NMR instrument at a
spinning rate of 5 KHz with 5'mm zirconium spinners. A 4 \xs 90° pulse sequence (pi)
was employed followed by variable durations. Typically, the spin locking pulse sequence
was applied ranging from 0.001 ms to 5 ms (16 different pulses) to the samples within the
expected range of relaxation time. The value of pulse power pi 11 used was the same as
pi (= 4 us) for relaxation measurement purposes. The number of pulse sequences
corresponded to the number of data points collected for relaxation calculation. Relaxation




4.1 Solid State Characterization of the Complexes
The solid state characterization studies suggest the formation of water soluble
complexes of P-sitosterol/polyethylene glycol. The solid state complexes were studied by
FT-IR and DSC.
4.1.1 Fourier Transform-Infrared Spectroscopy
The FT-IR spectra of the pure P-sitosterol, pure polyethylene glycol, and the
complex are shown in (Fig. 5). The FT-IR of the complex shows that the intensity of the
aliphatic tail of P-sitosterol (i.e. the C-H stretching 2876 -2900 cm'1) was slightly
decreased compared to the free P-sitosterol. This observation is consistent with
observation for theP-sitosterol/p-cyclodextrin complexes.
The OH group intensity of pure polyethylene glycol was weak because there are
only two terminal OH groups compared with many C-0 and C-H bonds. Additionally,
the OH peaks in the PEG/p-sitosterol is diminished in intensity compared to the free P-
sitosterol. This suggests the formation of a complex. The formation of the complex
lowers the possibility of intermolecular hydrogen bonding amongp-sitosterol molecules
because; in the complex the p-sitosterol is interacting with the PEG via van der Waals






Figure 5. FT-IR spectra of (a) p-sitosterol(b) polyethylene glycol and (c) the complex.
4.1.2 Differential Scanning Calorimetry
The melting point for PEG 2,000, 8,000, and 35,000 are 51.1 °C, 61.5°C, and
62.1°C respectively (see figures 6, 7, and 8). The melting point decreased when 10% (by
weight) of p-sitosterol was mixed with different molecular weights ofPEG (Table 1).
The decrease in the melting point is most likely because the P-sitosterol interferes with
the crystallization of PEG.62'64 The insertion of the P-sitosterol in between polymer chains
inhibits the alignment required for crystallization. The largest difference in melting point
was between 35,000 PEG alone and the mixture of 35,000 PEG with p-sitosterol. When
the 35,000 PEG interacted with 10% of P-sitosterol through hydrophobic interaction, the
formation of well-defined complexes inhibit crystallization. The interaction between the
p-sitosterol and lower molecular weight PEGs (2,000 and 8,000) is weaker and had a
smaller decrease in the glass transition temperature. The P-sitosterol was better
distributed within the 35,000 PEG because the longer chains permitted better van der
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Figure 8. DSC thermograms of 35,000 PEG alone and 35,000 PEG/p-sitosterol complex.



















To find the maximum possible amount of P-sitosterol that can be loaded into
complexes with the 35,000 PEG, the percentage of P-sitosterol was increased to 20% and
30%. Increasing the p-sitosterol content past 10% increased the PEG melting point after a
lowering of the melting point was observed at 10%. The melting point of the complex
with the higher P-sitosterol content was closer to the pure PEG, suggesting that
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increasing P-sitosterol past 10% results in a microphase separated system with separate
phases of PEG and p-sitosterol present (Fig. 9). Therefore, the results of our study
indicate that10% P-sitosterol was distributed very well distributed in matrix and
interacted well with the PEG through hydrophobic interactions.62 However, the PEG with
20% and 30% of P-sitosterol formed clusters (almost phase separated) in a PEG matrix


















Figure 9. DSC thermograms of 35,000 PEG and 35,000 PEG/p-sitosterol (10%, 20%,
30%) complexes.
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Table 2. Difference in MP between PEG 35,000 (62.06 °C) and the complex of the drug
















The Tip of P-sitosterol had the longest relaxation time (11.42 ms). The Tipof
polyethylene glycol was 4.99 ms and the complex with 10% P-sitosterol had the shortest
Tipof 3.08 ms (Table 3). The short Tipof the complex suggests that the system is more
amorphous and this observation supports the DSC results, which indicated that the
crystallinity is lower in the complex compared to the pure PEG. Additionally, it further
suggests that the P-sitosterol is embedded in the amorphous region of the PEG in the
matrix of the complex.






11.42 (Tip of the carbon with longest
relaxation time)
4.99 (methylene carbon)
3.08 (methylene carbon of PEG)
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4.2 Solution State Characterization of the Complexes
The administration of the complex as a therapeutic has to be carried out in the
solution state and therefore, it is necessary to characterize the formation of the complex
in the solution state. The complex in the solution state was studied by one-dimensional
(proton) and two-dimensional (2D) NMR spectroscopy (NOESY).
4.2.1 Proton Nuclear Magnetic Resonance (XH NMR)
*H NMR is beneficial for studying complexes in solution. P-sitosterol is insoluble
in H2O. The aqueous solubility of P-sitosterol was increased by the presence polyethylene
glycol. This observation is consistent with the polyethylene glycol's capability of
solubilizing hydrophobic compounds in aqueous media as a consequence of the
formation of a complex or a non-covalent adduct.64 !H NMR spectra of polyethylene
glycol as a function of P-sitosterol are displayed in Figure 10. As the P-sitosterol was
added in the same ratio to different molecular weights of polyethylene glycol, a
downfield shift the methylene protons of the PEG was observed (Table 4). The downfield





Figure 10. JH NMR chemical spectra (a)PEG 8,000 and (b) PEG with 10% p- sitosterol
content.
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Table 4. The'H NMR chemical shift of the PEG methylene groups as a function of























4.2.2 2D (NOESY)Proton Nuclear Magnetic Spectroscopy
Further evidence for the formation of a complex or a non-covalent adduct was
found in the 2D Nuclear Overhauser Effect Spectroscopy (NOESY) as shown in Figure
11. The NOESY spectrum displays cross peaks between the hydrophobic part of
polyethylene glycol (the methylene groups) with the aliphatic tail and with the cyclic
head of the P-Sitosterol. The NOESY results suggest that the P-sitosterol may have
different possible orientations as it interacts with the polyethylene glycol chain.62'63
Possible orientations include one of the two ends interacting with the methylene groups
of the PEG and also an orientation in which both ends simultaneously interact with the
PEG. The two ends simultaneously interacting with the PEG will make for a more stable
non-covalent adduct or complex because oftwo site of interactions is most likely stronger




Figure 11. 2D NOESY (500 MHz) of (3-sitosterol/polyethylene glycol complex in CDC13.
CHAPTER 5
CONCLUSION
The findings of this study indicate that hydrophobic interactions between the P-
sitosterol and polyethylene glycol results in the formation of a complex or a non-covalent
adduct. The complex or non-covalent adduct is water soluble whereas the pure P-
sitosterol is water insoluble. The differential scanning calorimetry studies suggest that the
complex with 10% (by weight) p-sitosterol is well distributed through out the matrix.
Increasing the p-sitosterol content to greater than 10% by weight in the complex results in
the formation ofp-sitosterol clusters, which diminishes the distribution of P-sitosterol
through out the matrix. The NOESY NMR results demonstrate different possibilities for
the orientation ofhow the P-sitosterol interacts with the polyethylene glycol. P-sitosterol
can interact through either the cyclic head or the aliphatic tail or both head and tail can
simultaneously interact with the methylene groups of the PEG. The level or strength of
interaction increases with increasing PEG molecular weight.
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